肺癌及肺炎患者血清脂联素检测分析

目的 研究脂联素在肺癌、肺炎患者血清中的水平,探讨其与疾病的关系及意义.方法 应用酶联免疫吸附试验方法检测70例肺癌患者(肺癌组)、65例肺炎患者(肺炎组)、60例健康体检者(健康对照组)的血清脂联素水平,对3组结果进行统计学处理并分析.结果 脂联素在健康对照组、肺炎组、肺癌组中的血清含量依次减少[分别为(11.46±6.93)、(9.69 ±6.12)、(5.91±4.49)mg/L],健康对照组与肺癌组比较差异有统计学意义(P＜0.01);肺炎组与肺癌组比较差异有统计学意义(P＜0.01).结论 脂联素在肺癌患者血清中含量的降低表明脂联素与肺癌的发生发展密切相关,其或许有可能成为治疗和检测肺癌的重要指标.

Abstract：

Objective To study serum levels of adiponectin in patients with lung cancer and pneumonia and to explore its relationship with clinical disease and significance. Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect 70 cases of lung cancer, 65 patients with benign lung diseases and 60 normal controls in the serum adiponectin levels, and the results were analyzed statistically. Results In healthy controls and benign lung disease group, serum adiponectin levels were higher than the lung cancer group. Serum adiponectin levels in healthy controls, benign lung disease group, and lung cancer group decreased in turn[(11.46 ±6.93)mg/L, (9.69 ±6.12) mg/L, (5.91±4.49) mg/L]. Between healthy control group and the lung cancer group there was significant difference (P＜0.01); between benign lung disease group and the lung cancer group there was significant difference (P＜0.01 ) too. Conclusion The low level of serum adipinectin in patients with lung cancer indicates that adiponectin is closely related with the development of lung cancer, and it might be used as an important indicator for the detection of treatment of lung cancer.

Detection and analysis of adiponectin in serum of patients with lung cancer and pneumonia

Objective To study serum levels of adiponectin in patients with lung cancer and pneumonia and to explore its relationship with clinical disease and significance. Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect 70 cases of lung cancer, 65 patients with benign lung diseases and 60 normal controls in the serum adiponectin levels, and the results were analyzed statistically. Results In healthy controls and benign lung disease group, serum adiponectin levels were higher than the lung cancer group. Serum adiponectin levels in healthy controls, benign lung disease group, and lung cancer group decreased in turn[(11.46 ±6.93)mg/L, (9.69 ±6.12) mg/L, (5.91±4.49) mg/L]. Between healthy control group and the lung cancer group there was significant difference (P＜0.01); between benign lung disease group and the lung cancer group there was significant difference (P＜0.01 ) too. Conclusion The low level of serum adipinectin in patients with lung cancer indicates that adiponectin is closely related with the development of lung cancer, and it might be used as an important indicator for the detection of treatment of lung cancer.